Efalizumab for Eczema

Inclusion Criteria: Adults (18 years or older) with atopic dermatitis with 5% or more body surface area involvement Investigator Global Assessment (IGA) score of "moderate" or worse In general good health with well-controlled medical problems Ability to provide written informed consent and comply with study assessments for the full duration of the study. If a female of childbearing potential, a negative pregnancy test and commitment to the use of two forms of effective contraception (birth control) for the duration of the study are necessary. If a non-sterile male, commitment to the use of two forms of effective contraception (birth control) for the duration of the study is necessary. Normal platelet count Exclusion Criteria: Patients with known hypersensitivity to efalizumab or any of its components Pregnancy or lactation Patients receiving immunosuppressive agents Prior enrollment in the study Participation in another simultaneous medical investigation or trial IGA score of "mild," "almost clear" or "clear" Systemic therapy for atopic dermatitis, phototherapy or topical therapy (other than moisturizer) within 1 week Medical condition which would make use of efalizumab unsafe; would limit compliance with study requirements; or would limit accurate assessment of efficacy. Ongoing, active, serious infection History of malignancy (except excised basal or squamous cell carcinoma of the skin)